Drugs and placebos: what’s the difference? by Benedetti, F
Science & Society
Drugs and placebos: what’s
the difference?
Understanding the molecular basis of the placebo effect could help clinicians to better use it in clinical
practice
Fabrizio Benedetti
D efining a drug is an easy task: It is amolecule delivered to the body toproduce a biological effect. Its mode
of action is to alter one or more biochemical
pathways, for instance, by binding to a
receptor or by modifying the activity of an
enzyme. Defining a placebo is a bit more
complicated. A placebo is usually defined in
pharmacological terms as an inert substance
with no pharmacological action. However,
this definition is superficial, as the effective-
ness of a placebo comprises many things,
including the words, rituals, symbols and
meanings that accompany its use. Thus, the
placebo is not the substance alone, but its
administration together with a concomitant
set of sensory and social stimuli that tell the
patient that he or she is being treated.
Indeed, a placebo is the entire ritual of the
therapeutic act.
Most of the confusion about the placebo
effect comes from the different usage and
meaning that clinicians who conduct a clinical
study and neuroscientists assign to the
word. Clinicians are generally interested in
any positive effects to be seen within a
control group of patients, regardless of the
cause of those effects. In the absence of a
drug, improvements can result from many
factors including the spontaneous remission
of a disease, statistical regression to the
mean, the patient or doctor’s bias, or the
patient’s expectation of improvement. By
contrast, neuroscientists are only interested
in those improvements that derive from
active processes in the patient’s brain, such
as expectations of benefit and learning
mechanisms. Clinical trials are only aimed
at establishing whether patients who take
the true treatment, be it pharmacological or
not, are better off than those who take the
placebo. Although this pragmatic approach
yields fruitful results in a clinical trial
setting, it is virtually useless to neuroscien-
tists who want to understand what is going
on in the brain when a placebo is given, that
is, when a therapeutic ritual is performed
without the actual administration of any
therapy.
......................................................
“. . . a placebo is the entire
ritual of the therapeutic act.”
......................................................
T aking these considerations intoaccount, the placebo effect acquiresan important biological meaning and
represents an excellent model for the neuro-
scientist to understand how the human brain
works. Indeed, the vast expansion of
placebo research over the past decades has
taught us that many mechanisms are
involved, ranging from modulation of anxiety
to activation of reward mechanisms, from
classical associative conditioning to social
learning and from genetics to different
personality traits. There is not one single
placebo effect, but many, each with different
mechanisms across a variety of medical
conditions and therapeutic interventions.
Similar to our better understanding of
cancer, in which different mechanisms are
responsible for different types of the disease,
we have learned over the past few years that
the question “What is the mechanism of the
placebo effect?” is wrong. A better question
is: “What are the mechanisms across different
conditions?”
......................................................
“. . . humans are endowed
with endogenous systems that
can be activated by verbally
induced positive expectations,
therapeutic rituals, healing
symbols, and, more generally,
by social interactions”
......................................................
One of the most interesting aspects of
placebo research is related to the newly
emerging concept that placebos activate the
same biochemical pathways that are acti-
vated by the drugs we administer in routine
medical practice. This view is an interesting
challenge from both an evolutionary and a
neurobiological point of view. In other
words, humans are endowed with endoge-
nous systems that can be activated by
verbally induced positive expectations,
therapeutic rituals and healing symbols and,
more generally, by social interactions. For
example, there is now compelling experi-
mental evidence that placebo analgesia can
be mediated by at least two systems: the
endogenous opioid system and the endoc-
annabinoid system [1, 2]. In addition, the
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cholecystokinergic system can modulate the
opioid system so as to produce placebo
responses of different magnitudes [3].
Likewise, administration of placebo to
Parkinson patients induces the release of
dopamine in the striatum [4]. These obser-
vations represent an epochal transition from
general concepts, such as suggestibility and
power of mind, to a true physiology of the
placebo effect.
T his new perspective may haveprofound implications both in routinemedical practice and in clinical
trials. For example, when morphine is
administered, it binds to opioid receptors
and inhibits pain transmission, but at the
same time, the ritual of its administration
induces the activation of the same opioid
receptors. Similarly, when an anti-Parkinson
dopaminergic drug is given, it stimulates
dopamine receptors, but at the same time,
the ritual of its administration activates the
same dopamine receptors. Considering that
drugs and placebos share common receptors
and biochemical pathways, one of the main
challenges is therefore to understand the
similarities and differences between the
actions of drugs and those of placebos.
Despite these common pathways, clear
differences do exist in some conditions
including pain and Parkinson’s disease:
duration of action, variability of the effect
and magnitude of the effect.
In general, the duration of the effect of a
drug is longer than that of a placebo. As far
as we know, this holds true for painkillers
and anti-Parkinson agents, whereas much
less is known about other therapeutic inter-
ventions. For example, the effect of the
powerful anti-Parkinson drug apomorphine
lasts much longer on average than that of a
placebo. The variability of the effectiveness
of a drug is also much lower than that of a
placebo; the effectiveness of drugs is fairly
consistent, while the effectiveness of placebo
ranges widely across patients.
However, when a placebo is effective, the
magnitude of that effect matches that of a
drug. For example, some good placebo
responders may show a reduction in the
UPDRS (Unified Parkinson’s Disease Rating
Scale) by up to 50%, similar to drugs [5].
The placebo effect can be even larger in pain
reduction up to 5–6 points on a scale ranging
from 0 (no pain) to 10 (unbearable pain);
drug companies go to great lengths to
produce drugs that reduce pain by 2–3
points. In irritable bowel syndrome, the
analgesic response to a placebo can be even
larger than to lidocaine [6]. However, it is
important to point out that only a small
percentage of placebo responders show such
huge effects. Owing to the response variability,
the average magnitude is significantly larger
for drugs compared with placebos.
Duration, variability and magnitude are
related to efficacy, and we can also make
several considerations about toxicity. In fact,
placebos may produce so-called nocebo or
negative effects, which represent the evil
twin of the placebo effect. Patients who
receive placebo in analgesic clinical trials for
migraine, for example, often report a high
frequency of adverse events. These negative
effects correspond to those expected of the
anti-migraine medication against which the
placebo is compared. For example, anorexia
and memory difficulties, which are typical
adverse events of anti-convulsants, are
present only in the placebo group of such
trials, which suggests that the adverse
events in placebo arms of clinical trials of
anti-migraine medications depend on the
adverse events of the active medication
against which the placebo is compared.
These findings are in keeping with the
important role of expectation in the placebo/
nocebo phenomenon, such that sometimes
patients get what they expect, perhaps from
reading the side effect information of the
real drug. The number of dropouts in clini-
cal trials owing to nocebo effects is a crucial
aspect that may confound the interpretation
of many clinical trials.
M uch less is known about thebiological mechanisms of nocebos,mainly because of the ethical limi-
tations of giving negative information to
patients. Today we know that anticipatory
anxiety plays a key role, and anxiety triggers
the activation of cholecystokinin, which, in
turn, facilitates pain transmission [7]. A
deactivation of endogenous opioids and
dopamine has also been found to take part
in the nocebo phenomenon [8].
Similarities and differences between
drugs and placebos are not confined to the
classical clinical setting: Placebos can repro-
duce some effects of recreational drugs and
cognitive performance-boosting drugs.
Moreover, placebos may also show effects
similar to those of the ergogenic drugs used
in sport to increase physical performance.
This raises important ethical and legal issues
for anti-doping agencies, since placebos—
which are not detectable in blood or urine—
have been found to increase performance in
some conditions [9]. The question is thus
whether it is ethical to use placebo proce-
dures in sport to mimic the ergogenic action
of drugs.
Several important questions also arise as
to how to exploit the placebo effect in
routine clinical practice. However, two
opposite questions can be posed, depending
on the setting in which placebos are admin-
istered. In routine clinical practice, one
wants to maximize the placebo effect, so the
main question in which physicians are inter-
ested is: “How can we decrease the variability
and increase the duration and magnitude of
placebo effects?” By contrast, in clinical
trials, we want to minimize the placebo
response in order to better emphasize the
drug effect; thus, those conducting clinical
trials would like to answer the question:
“How can we decrease variability, duration
and magnitude of placebo effects?”.
......................................................
“There is a growing tendency
to justify any bizarre procedure
and healing practice by claim-
ing that they may induce posi-
tive expectations and outcomes
via the placebo effect”
......................................................
T oday, we are in a good positionto partially resolve these twochallenges. Indeed, it is possible to
manipulate, at least in part, the placebo
response in both directions. First, by using a
learning procedure, we can decrease vari-
ability and increase duration and magnitude.
To do this, pharmacological pre-conditioning
is carried out whereby a real drug is admin-
istered for several days before it is replaced
with a placebo. Most patients show huge
placebo responses, which indicates that
learning plays a key role in the placebo
effect. This is desirable in routine medical
practice, as it is then possible to reduce drug
intake in the long run. Second, by using a
negative conditioning procedure—which
creates a mismatch between what the
patient expects and what he or she gets—it
is possible to decrease the magnitude of the
placebo effect. Doing this is necessary for
clinical trials, as subjects with low placebo
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responses can be better compared with
subjects who take the active treatment.
Unfortunately, this negative conditioning
procedure can only control for the learning
component of the placebo effect, but it has
no effect on spontaneous remission and
regression to the mean.
A better understanding of the similari-
ties and differences between drugs and
placebos represents an important challenge
for future research, which will lead to
better medical practice and better interpre-
tation of clinical trials. The crucial starting
point is the understanding of the biological
underpinnings of placebos and their
relationship to drug action. As far as we
know, at least two possibilities can be
envisaged: Drugs and placebos can act
either on the same receptors or, otherwise,
on the same type of receptor but in different
regions of the central nervous system, for
example in pain (Fig 1). There is some
experimental evidence that the second
mechanism is more likely. For example,
narcotics bind to the mu-opioid receptors
in one region of the brain, whereas placebos
act, through the activation of endogenous
ligands, on mu-opioid receptors in a
different region, with an overall additive
effect [10].
D espite these recent insights into theneurobiology of placebo effects,there is a paradox in placebo
research: The more we know, the more
difficult our correct communication to the
general public seems to become. Indeed,
there is danger lurking around the corner.
As placebo responses can be triggered by the
very ritual of the therapeutic act, any thera-
peutic ritual can, in principle, activate the
same biochemical mechanisms. If fake pills
prescribed by doctors can generate positive
expectations and outcomes, so talismans
handed out by quacks and bizarre rituals
performed by shamans may also induce
positive expectations.
There is a growing tendency to justify
any bizarre procedure and healing practice
by claiming that they may induce positive
expectations and outcomes via the placebo
effect. After the discovery that endocannabi-
noids are activated by placebos and positive
expectations [2], I was contacted by many
people with weird and eccentric proposals
aimed at enhancing expectations, beliefs,
trust and hope. These individuals often
claim that any procedure that increases
expectations and beliefs is justified, no
matter where it comes from. This is a worri-
some future perspective that we should
avoid by improving good communication
between science, ethics and the media. The
results of placebo research should be better
explained to both journalists and the general
public, because misuse could have a devas-
tating social impact and undermine the
credibility of modern medicine itself. The
future ethical and biological debate promises
to be exciting and stimulating, for we are
dealing with the foibles and vulnerable
aspects of human beings: expectation, belief,
trust, hope and suggestibility. Understanding
their underlying biology is exciting, but it
may turn out to be dangerous and alarming
if badly exploited.
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Figure 1. Two possible mechanisms of action of opioid drugs and placebos.
Opioids and placebos (through the activation of endogenous ligands) may act on the very same l receptors
located in the same region of the brain or, otherwise, they may act on the same type of opioid receptors but in
different regions.
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